

**ATTACHMENT A**  
**Amendments to the Claims**

*This listing of claims will replace all prior versions, and listings, of claims in the application.*

1. (Original) Combinations of an antiemetic agent with an enkephalinase inhibitor.
2. (Original) The combination according to claim 1, wherein said anti emetic is a 5-HT<sub>3</sub> receptor antagonist.
3. (Original) The combination according to claim 2, wherein said 5-HT<sub>3</sub> receptor antagonist is selected from the group consisting of ondansetron and granisetron.
4. (Currently Amended) The combination according to ~~any one of the preceding claims~~ claim 1 wherein said enkephalinase inhibitor is selected from the group consisting of racecadotril and dexecadotril.
5. (Currently Amended) A pharmaceutical composition comprising the combination according to ~~any one of the preceding claims~~ claim 1, and a pharmaceutically acceptable vehicle or excipient.
6. (Original) The pharmaceutical composition according to claim 5, wherein said pharmaceutical composition is for simultaneous, separate or sequential administration of said enkephalinase inhibitor and said antiemetic agent.
7. (Currently Amended) The pharmaceutical composition according to claim 5 ~~or 6~~, wherein said pharmaceutical composition is suitable for oral administration.
8. (Currently Amended) The pharmaceutical composition according to ~~any one of claims 5 to 7~~ claim 5, wherein said pharmaceutical composition is in the form of tablets, capsules or granulated powder.

9. (Currently Amended) The pharmaceutical composition according to ~~anyone of claims 5 to 8~~ claim 5, wherein said pharmaceutical composition of the invention comprises between 50 and 100 mg of said enkephalinase inhibitor per dosage unit for adults and corresponding doses according to body weight for children and babies.

10. (Currently Amended) The pharmaceutical composition according to ~~anyone of claims 5 to 9~~ claim 5 wherein said pharmaceutical composition comprises between 1 and 8 mg of a 5-HT<sub>3</sub> antagonist per dosage unit for adults and corresponding doses according to body weight for children and babies.

11. (Currently Amended) The pharmaceutical according to ~~anyone of claims 5 to 10~~ claim 5 wherein said pharmaceutical composition comprises between 2 and 8 mg of ondansetron per dosage unit for adults and corresponding doses according to body weight for children and babies.

12. (Currently Amended) The pharmaceutical composition according to ~~anyone of claims 5 to 11~~ claim 5, wherein said pharmaceutical composition comprises between 1 and 4 mg of granisetron per dosage unit for adults and corresponding doses according to body weight for children and babies.

13. (Currently Amended) The pharmaceutical composition according to ~~anyone of claims 5 to 12~~ claim 5, wherein said pharmaceutical composition comprises the combination of the invention in the same dosage unit.

14. (Currently Amended) Use of the combination of an antiemetic agent with an enkephalinase inhibitor according to ~~anyone of claims 1 to 4~~ in the preparation of a pharmaceutical composition according to ~~anyone of claims 5 to 13~~ claim 5 for the treatment of acute gastroenteritis.

15. (Currently Amended) Use of the combination of an antiemetic agent with an enkephalinase inhibitor according to ~~anyone of claims 1 to 4~~ in the preparation of a

pharmaceutical composition according to ~~anyone of claims 5 to 13~~ claim 5 for the treatment of acute ~~diarrhoea~~ diarrhea associated with emesis.

16. (Currently Amended) Use according to claim 15, wherein said diarrhoea is chemotherapy- induced ~~diarrhoea~~ diarrhea, carcinoid ~~diarrhoea~~ diarrhea, traveller's ~~diarrhoea~~ diarrhea, ~~diarrhoea~~ diarrhea elicited by various bacteria, viruses or parasites.

17. (Currently Amended) Use according to ~~anyone of claims 14 to 16~~ claim 14, wherein said treatment comprises oral administration, preferably two to four times a day.

18. (Currently Amended) Use according to the combinations of an antiemetic agent with an enkephalinase inhibitor in the preparation of a pharmaceutical composition ~~anyone of claims 14 to 17~~, wherein said treatment comprises administration of the composition according to ~~anyone of claims 5 to 13~~ claim 5 two to four times a day.

19. (Currently Amended) Use according to ~~anyone of claims 14 to 18~~ claim 14, wherein said combination comprises dexecadotril and ondansetron for the preparation of a pharmaceutical composition for the treatment of acute gastroenteritis by simultaneous, separate or sequential oral administration of the active ingredients.